A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS)

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 31, Issue 10, 2012, Pages 2703-2711

  Paes, B ^a   Mitchell, I ^b   Li, A ^c   Lanctot K L ^c,d  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; DRUG USE; FEMALE; GESTATIONAL AGE; HOSPITALIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RESPIRATORY TRACT INFECTION;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIVIRAL AGENTS; BIRTH WEIGHT; CANADA; FEMALE; GESTATIONAL AGE; HOSPITALIZATION; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; MALE; PREGNANCY; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; SEASONS; SMOKING; TREATMENT OUTCOME;

EID: 84869117365     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-012-1617-7     Document Type: Article

References (51)

1. IMpact-RSV Study Group (1998) Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 102(3 Pt 1):531-537
2. Committee on Infectious Diseases (2009) From the American Academy of Pediatrics: Policy statements-Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 124:1694-1701
3. Deutsche Gesellschaft für Pädiatrische Infektiologie (DGPI); Deutsche Gesellschaft für Pädiatrische Kardiologie (DGPK); Gesellschaft für Pädiatrische Pneumologie (GPP); Gesellschaft für Neonatologie und Pädiatrische Intensivmedizin (GNPI) (2006) Stellungnahme zur Prophylaxe von schweren RSV-Erkrankungen bei Risikokindern mit Palivizumab. http://www.dgpi.de/pdf/Leitlinie-Palivi zumab-27Okt2006.pdf. Accessed January 2012
4. Figueras Aloy J, Carbonell Estrany X; Comité de Estándares de la Sociedad Española de Neonatología (2010) Recommendations for the use of palivizumab in the prevention of respiratory syncytial virus infection in late preterm infants (32(1) to 35(0) weeks of gestation). An Pediatr (Barc) 73(2):98.e1-98.e4
5. Figueras Aloy J, Quero J, Doménech E, López Herrera MC, Izquierdo I, Losada A, Perapch J, Sánchez-Luna M; Comité de Estándares de la Sociedad Española de Neonatología (2005) Recommendations for the prevention of respiratory syncytial virus infection. An Pediatr (Barc) 63(4):357-362
6. Resch B, Berger A, Bernert G, Eber E, Frischer T, Simma B, Zacharasiewicz A, Zach M (2008) Konsensuspapier zur prophylaxe der RSV-infektion mit palivizumab und post-RSVatemwegserkrankung. Monatsschr Kinderheilkd 156:381-383
7. Robinson JL; Canadian Paediatric Society, Infectious Diseases and Immunization Committee (2011) Preventing respiratory syncytial virus infections. Paediatr Child Health 16(8):488-490
8. Rondini G, Macagno F, Barberi I (2004) Raccomandazioni della Società Italiana di Neonatologia per la prevenzione delle malattie da virus respiratorio sinciziale (VRS). Acta Neonatologica 1:1-11
9. Carbonell-Estrany X, Simões EA, Fullarton JR, Ferdynus C, Gouyon JB; European RSV Risk Factor Study Group (2010) Validation of a model to predict hospitalization due to RSV of infants born at 33-35 weeks' gestation. J Perinat Med 38(4):411-417
10. Figueras-Aloy J, Carbonell-Estrany X, Quero J; IRIS Study Group (2004) Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain. Pediatr Infect Dis J 23(9):815-820
11. Law BJ, Langley JM, Allen U, Paes B, Lee DS, Mitchell I, Sampalis J, Walti H, Robinson J, O'Brien K, Majaesic C, Caouette G, Frenette L, Le Saux N, Simmons B, Moisiuk S, Sankaran K, Ojah C, Singh AJ, Lebel MH, Bacheyie GS, Onyett H, Michaliszyn A, Manzi P, Parison D (2004) The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J 23(9):806-814
12. Sampalis JS, Langley J, Carbonell-Estrany X, Paes B, O'Brien K, Allen U, Mitchell I, Aloy JF, Pedraz C, Michaliszyn AF (2008) Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation. Med Decis Making 28(4):471-480
13. Simões EA, Carbonell-Estrany X, Fullarton JR, Liese JG, Figueras-Aloy J, Doering G, Guzman J; European RSV Risk Factor Study Group (2008) A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33-35 weeks of gestational age, based on data from the Spanish FLIP Study. Respir Res 9:78
14. Simões EA, Carbonell-Estrany X, Fullarton JR, Rossi GA, Barberi I, Lanari M; European RSV Risk Factor Study Group (2011) European risk factors' model to predict hospitalization of premature infants born 33-35 weeks' gestational age with respiratory syncytial virus: validation with Italian data. J Matern Fetal Neonatal Med 24(1):152-157
15. Stensballe LG, Fullarton JR, Carbonell-Estrany X, Simões EA (2010) Population based external validation of a European predictive model for respiratory syncytial virus hospitalization of premature infants born 33 to 35 weeks of gestational age. Pediatr Infect Dis J 29(4):374-376
16. Horn SD, Smout RJ (2003) Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J Pediatr 143(5 Suppl):S133-S141
17. Law B, Macdonald N, Langley J, Mitchell I, Stephens D, Wang E, Robinson J, Boucher F, McDonald J, Dobson S (1998) Severe respiratory syncytial virus infection among otherwise healthy prematurely born infants: What are we trying to prevent? Paediatr Child Health 3(6):402-404
18. Willson DF, Landrigan CP, Horn SD, Smout RJ (2003) Complications in infants hospitalized for bronchiolitis or respiratory syncytial virus pneumonia. J Pediatr 143(5 Suppl):S142-S149
19. Mitchell I, Paes BA, Li A, Lanctôt KL; CARESS investigators (2011) CARESS: the Canadian registry of palivizumab. Pediatr Infect Dis J 30(8):651-655
20. Berner R, Schwoerer F, Schumacher RF, Meder M, Forster J (2001) Community and nosocomially acquired respiratory syncytial virus infection in a German paediatric hospital from 1988 to 1999. Eur J Pediatr 160(9):541-547
21. Boyce TG, Mellen BG, Mitchel EF Jr, Wright PF, Griffin MR (2000) Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr 137(6):865-870
22. Meert K, Heidemann S, Abella B, Sarnaik A (1990) Does prematurity alter the course of respiratory syncytial virus infection? Crit Care Med 18(12):1357-1359
23. Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM (2000) Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis. Arch Pediatr Adolesc Med 154 (1):55-61
24. Wang EE, Law BJ, Boucher FD, Stephens D, Robinson JL, Dobson S, Langley JM, McDonald J, MacDonald NE, Mitchell I (1996) Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of admission and management variation in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr 129(3):390-395
25. Weigl JA, Puppe W, Schmitt HJ (2001) Incidence of respiratory syncytial virus-positive hospitalizations in Germany. Eur J Clin Microbiol Infect Dis 20(7):452-459
26. Heikkinen T, Valkonen H, Lehtonen L, Vainionpää R, Ruuskanen O (2005) Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis. Arch Dis Child Fetal Neonatal Ed 90(1):F64-F68
27. Damore D, Mansbach JM, Clark S, Ramundo M, Camargo CA Jr (2008) Prospective multicenter bronchiolitis study: predicting intensive care unit admissions. Acad Emerg Med 15(10):887-894
28. Kneyber MC, Brandenburg AH, de Groot R, Joosten KF, Rothbarth PH, Ott A, Moll HA (1998) Risk factors for respiratory syncytial virus associated apnoea. Eur J Pediatr 157 (4):331-335
29. Ralston S, Hill V (2009) Incidence of apnea in infants hospitalized with respiratory syncytial virus bronchiolitis: a systematic review. J Pediatr 155(5):728-733
30. Schiller O, Levy I, Pollak U, Kadmon G, Nahum E, Schonfeld T (2011) Central apnoeas in infants with bronchiolitis admitted to the paediatric intensive care unit. Acta Paediatr 100(2):216-219
31. Sampalis JS (2003) Morbidity and mortality after RSV-Associated hospitalizations among premature Canadian infants. J Pediatr 143 (5 Suppl):S150-S156
32. Méndez Rubio I, Lázaro de Mercado P, Carbonell Estrany X, Figueras Aloy J; Grupo IRIS (2010) Quality of life of preterm infants and admissions due to respiratory infections. An Pediatr (Barc) 73(3):121-131
33. Welliver RC Sr, Checchia PA, Bauman JH, Fernandes AW, Mahadevia PJ, Hall CB (2010) Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy children. Curr Med Res Opin 26(9):2175-2181
34. Holman RC, Shay DK, Curns AT, Lingappa JR, Anderson LJ (2003) Risk factors for bronchiolitis-Associated deaths among infants in the United States. Pediatr Infect Dis J 22(6):483-490
35. Lanctôt KL, Masoud ST, Paes BA, Tarride JE, Chiu A, Hui C, Francis PL, Oh PI (2008) The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis. Curr Med Res Opin 24(11):3223-3237
36. Lázaro y de Mercado P, Figueras Aloy J, Doménech Martínez E, Echániz Urcelay I, Closa Monasterolo R, Wood Wood MA, Fitch Warner K (2006) The efficiency (cost-effectiveness) of palivizumab as prophylaxis against respiratory syncytial virus infection in premature infants with a gestational age of 32-35 weeks in Spain. An Pediatr (Barc) 65(4):316-324
37. Resch B, Sommer C, Nuijten MJ, Seidinger S,Walter E, Schoellbauer V, MuellerWD (2012) Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-Term epidemiologic data from Austria. Pediatr Infect Dis J 31(1):e1-e8
38. Frogel M, Nerwen C, Cohen A, Vanveldhuisen P, Harrington M, BoronM; Palivizumab Outcomes Registry Group (2008) Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J Perinatol 28(7):511-517
39. Langley GF, Anderson LJ (2011) Epidemiology and prevention of respiratory syncytial virus infections among infants and young children. Pediatr Infect Dis J 30(6):510-517
40. Simões EA (2003) Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr 143(5 Suppl):S118-S126
41. Sommer C, Resch B, Simões EA (2011) Risk factors for severe respiratory syncytial virus lower respiratory tract infection. Open Microbiol J 5:144-154
42. Al-Shehri MA, Sadeq A, Quli K (2005) Bronchiolitis in Abha, Southwest Saudi Arabia: viral etiology and predictors for hospital admission. West Afr J Med 24(4):299-304
43. Carbonell-Estrany X, Quero J; IRIS Study Group (2001) Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons. Pediatr Infect Dis J 20(9):874-879
44. von Linstow ML, Høgh M, Nordbø SA, Eugen-Olsen J, Koch A, Høgh B (2008) A community study of clinical traits and risk factors for humanmetapneumovirus and respiratory syncytial virus infection during the first year of life. Eur J Pediatr 167(10):1125-1133
45. Semple MG, Taylor-Robinson DC, Lane S, Smyth RL (2011) Household tobacco smoke and admission weight predict severe bronchiolitis in infants independent of deprivation: prospective cohort study. PLoS One 6(7):e22425
46. Holberg CJ, Wright AL, Martinez FD, Ray CG, Taussig LM, Lebowitz MD (1991) Risk factors for respiratory syncytial virusassociated lower respiratory illnesses in the first year of life. Am J Epidemiol 133(11):1135-1151
47. Liese JG, Grill E, Fischer B, Roeckl-Wiedmann I, Carr D, Belohradsky BH; Munich RSV Study Group (2003) Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany. Eur J Pediatr 162(4):230-236
48. Sritippayawan S, Prapphal N, Wong P, Tosukhowong P, Samransamruajkit R, Deerojanawong J (2006) Environmental tobacco smoke exposure and respiratory syncytial virus infection in young children hospitalized with acute lower respiratory tract infection. J Med Assoc Thai 89(12):2097-2103
49. Castro SM, Chakraborty K, Guerrero-Plata A (2011) Cigarette smoke suppresses TLR-7 stimulation in response to virus infection in plasmacytoid dendritic cells. Toxicol In Vitro 25(5):1106-1113
50. Modestou MA, Manzel LJ, El-Mahdy S, Look DC (2010) Inhibition of IFN-gamma-dependent antiviral airway epithelial defense by cigarette smoke. Respir Res 11:64
51. Paes B, Steele S, Janes M, Pinelli J (2009) Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada. Curr Med Res Opin 25(7):1585-1591